0.040302464$71.480.3882ThermoFisher0.3524SCTENTIFIO0.3229$11.93$46.030.7510.1999$37.150.6996$5.970.526888.110.26330.4297$46.540.61580.46210.2034BANOINGPRESSUREANDPOSSIBILTTYThe Pulse 2026Global R&D insights in pharmaceuticalsppd
ContentsMethodologyExecutivesummary8Detailed findings: Challenges, strategies and state of the indlustry心Datailecdfindinas:Patient-focused strateqiesGDetailed findinas:Al/MIin clinical develooment30Detailed findinas: Outsourcing32AppendixThePulse2026ppd.com.
About The PulseThe future for drua developers is increasingl shaped by their ability toadopt innovative strategies and new technologies while navigating anenvironment marked by complexity and rapid change.That's why the PPD"*clinical research business of Thermo FisherScientificsurveved 150 leaders at biotech and oharmaceuticaorganizations around the globe to assess trends in drug discoveryand development. Respondents shared barriers to bringing drugs tomarket, inovations influencing progress, and perspectives on topicssuch as Al, patient recruitment, the regulatory landscape and moreNow in its fourth vear,. The Pulse reveals a stark throuahline:uncertainty has become the dominant backdrop for druqdevelopment. Manv of the past vear's shifts-economic pressuresevoling care models, requlatory recalibration and rising expectationsto do more with less-continue to reverberate. As companiesshoreup investments and reassess their portfolios. leaders are araoolingwith immenseoressure todeliverinan environment wherethearoundkeepsmovina.are navigating shifing sands: balancing long-term scientific ambitionwith short-term operational realities. confrontina challenaes that arebecomina more intertwined and less predictable. and working tomaintain momentum despite forces largely outside their controlThe Pulse aoes bevond the numbers to explore what this pervasiveuncertainty means fr R&D teams today, and how leadingorganizations are positioning themselves to stay resilient. makeconfident decisions, and continue advancing therapies for patients inthe year ahead.ThePulse2026ppd.com;
MethodologyThePulse2026ppd.com.
Methodoloay and sample,Respondents? Web-based, quantitative survey with supplementa。 Employed by a pharma, biopharma, or biotechin-depth interviews;company with one or more uniaue molecules,compounds in developmentQuotar:1=150 (n=-61Large companies,Job Level:DirectororhiaherLocations:U.S..Canada. Europe.Asia/AustraliaPrimary responsibilitiesin one of theefollowing areas:Dates:Julv to Auaust2025Survey vendor/Sample source:LifeScience Peri-/post-approvalregistries/HEORStrategyGroup(LSSGQuality/Requlatory,The PPD" cinical research businesof Business services (finance, procurement/purchasing,Thermo Fisher Scientific was not identifiedvendormanagement)as the research sponsorExecutive management/C-level Decision-making responsibilty in one or more drugdevelopment phases (pre-cliical through Phase IV,late stage/registries)Highly or somewhat involved in selecting vendorsfor ical ia seices tng dscovery throughPhaseM)Large=...
